{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:08:00Z","timestamp":1782173280648,"version":"3.54.5"},"reference-count":34,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi K.K."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Prurigo nodularis (PN) is associated with considerable disease burden. Limited information exists about the epidemiology, treatment patterns, and impact of PN. This retrospective study used Japanese health insurance claims data to investigate the prevalence and incidence of PN from 2006 to 2021. Methods: A cross-sectional study design was used to estimate prevalence and incidence longitudinally; a cohort design was used to assess comorbidities, treatment patterns, and healthcare resource utilization (HCRU). Results: Over the study period, data from 297,545 to 10,081,414 individuals were available annually; in 2020, 1946 individuals were diagnosed with PN. The prevalence and incidence of PN showed little variation over the study period; in 2021, the prevalence was 41 per 100,000 persons. Although there was a tendency for a higher prevalence of PN in childhood, the prevalence and incidence were similar in other age groups and were slightly higher in females. Inflammatory skin diseases and atopic diathesis were common comorbidities. The most prescribed treatments for adults with PN were topical steroids (78%), oral antihistamines (68%), and moisturizers (54%). Oral steroids, macrolides, and psychotropics were prescribed to &gt;10% of patients. Individuals with PN who also had atopic dermatitis (AD) received higher cumulative doses of stronger potency topical steroids, local steroid injections, and oral steroids than those without concomitant AD. Additionally, HCRU was higher in individuals with AD. Conclusions: Although patients are usually treated according to the guidelines, there is an unmet need for more effective treatments for PN due to the frequent use of intensive and late-line treatments.<\/jats:p>","DOI":"10.3390\/jcm14061872","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T06:52:30Z","timestamp":1741675950000},"page":"1872","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Status of Prurigo Nodularis in Japan: A Retrospective Study Using a Health Insurance Claims Database"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5903-3187","authenticated-orcid":false,"given":"Atsuyuki","family":"Igarashi","sequence":"first","affiliation":[{"name":"Igarashi Dermatology Higashigotanda, Tokyo 141-0022, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2916-0759","authenticated-orcid":false,"given":"Takuo","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi K.K., Tokyo 163-1488, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Sunaga","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi K.K., Tokyo 163-1488, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakatsu","family":"Nawata","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi K.K., Tokyo 163-1488, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-8787","authenticated-orcid":false,"given":"Kazuhiko","family":"Arima","sequence":"additional","affiliation":[{"name":"Medical Affairs, Sanofi K.K., Tokyo 163-1488, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"ref_1","first-page":"e414","article-title":"2020 guidelines for the diagnosis and treatment of prurigo","volume":"48","author":"Satoh","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis: Epidemiology and clinical features","volume":"83","author":"Huang","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: Pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","article-title":"Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial","volume":"79","author":"Steinke","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00403-020-02148-0","article-title":"The impact of prurigo nodularis on quality of life: A systematic review and meta-analysis","volume":"313","author":"Janmohamed","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1111\/jdv.16309","article-title":"Chronic nodular prurigo: Clinical profile and burden. A European cross-sectional study","volume":"34","author":"Pereira","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/1346-8138.17045","article-title":"Disease burden and treatment satisfaction in patients with prurigo nodularis in Japan","volume":"51","author":"Murota","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","article-title":"IFSI-guideline on chronic prurigo including prurigo nodularis","volume":"5","author":"Pereira","year":"2020","journal-title":"Itch"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2023.08.011","article-title":"Dupilumab as a novel treatment option for prurigo nodularis","volume":"154","author":"Nakajima","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000246715","article-title":"Prurigo nodularis consists of two distinct forms: Early-onset atopic and late-onset non-atopic","volume":"190","author":"Tanaka","year":"1995","journal-title":"Dermatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: Aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jgf2.422","article-title":"Data resource profile: JMDC claims database sourced from health insurance societies","volume":"22","author":"Nagai","year":"2021","journal-title":"J. Gen. Fam. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.2169\/internalmedicine.50.5266","article-title":"Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: Current status of adherence to clinical guidelines and related factors","volume":"50","author":"Kirigaya","year":"2011","journal-title":"Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2169\/internalmedicine.50.4344","article-title":"Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson\u2019s disease","volume":"50","author":"Nakaoka","year":"2011","journal-title":"Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jaci.2017.07.049","article-title":"Childhood chronic prurigo: Interest in patch tests and delayed-reading skin prick tests to environmental allergens","volume":"141","author":"Maridet","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","article-title":"A nationwide study of prurigo nodularis: Disease burden and healthcare utilization in the United States","volume":"141","author":"Wongvibulsin","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"adv00309","DOI":"10.2340\/00015555-3655","article-title":"Epidemiology of prurigo nodularis compared with psoriasis in Germany: A claims database analysis","volume":"100","author":"Ketz","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Woo, Y.R., Wang, S., Sohn, K.A., and Kim, H.S. (2021). Epidemiology, comorbidities, and prescription patterns of Korean prurigo nodularis patients: A multi-institution study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010095"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/1346-8138.14947","article-title":"Health-care resource use and current treatment of adult atopic dermatitis patients in Japan: A retrospective claims database analysis","volume":"46","author":"Igarashi","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/1346-8138.13392","article-title":"Clinical practice guidelines for the management of atopic dermatitis 2016","volume":"43","author":"Saeki","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Machida, M., Nishioka, Y., Noda, T., and Imamura, T. (2023). Research note changes in the number of outpatient visits in Japan during the COVID-19 pandemic. BMC Res. Notes, 16.","DOI":"10.1186\/s13104-023-06336-9"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Makiyama, K., Kawashima, T., Nomura, S., Eguchi, A., Yoneoka, D., Tanoue, Y., Kawamura, Y., Sakamoto, H., and Shi, S. (2021). Trends in Healthcare Access in Japan during the First Wave of the COVID-19 Pandemic, up to June 2020. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18063271"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Whang, K.A., Kang, S., and Kwatra, S.G. (2019). Inpatient burden of prurigo nodularis in the United States. Medicines, 6.","DOI":"10.3390\/medicines6030088"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.clindermatol.2023.10.001","article-title":"The top 100 most cited contributions on prurigo nodularis: A bibliometric analysis","volume":"41","author":"Andre","year":"2023","journal-title":"Clin. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1346-8138.2011.01209.x","article-title":"Prevalence of dermatological disorders in Japan: A nationwide, cross-sectional, seasonal, multicenter, hospital-based study","volume":"38","author":"Furue","year":"2011","journal-title":"J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1111\/jdv.17485","article-title":"Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: A population-based claims data analysis","volume":"35","author":"Augustin","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"adv00155","DOI":"10.2340\/00015555-3518","article-title":"Prevalence of prurigo nodularis in Poland","volume":"100","author":"Ryczek","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/1346-8138.17400","article-title":"Current clinical practice of prurigo nodularis in Japan: A cross-sectional web-survey among dermatologists","volume":"52","author":"Murota","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMe1916733","article-title":"Breaking the itch-scratch cycle in prurigo nodularis","volume":"382","author":"Kwatra","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1111\/jdv.18903","article-title":"Chronic prurigo: Insufficient disease control in spite of high healthcare usage","volume":"37","author":"Pereira","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1872\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:20Z","timestamp":1760028620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14061872"],"URL":"https:\/\/doi.org\/10.3390\/jcm14061872","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]}}}